Home » Newsletters » BioWorld

BioWorld

Sep. 2, 1993

View Archived Issues

PERSEPTIVE TO ACQUIRE MASS SPECTROMETRY COMPANY

CLOT-BUSTER STUDY RESULTS PUBLISHED

IMMUNOGEN TESTS ONCOLYSIN S

IVAX COMPLETES JOHNSON PRODUCTS MERGER

STOCK PURCHASE BRINGS VIRATEK $14M

VESTAR ENTERS TAXOL MARKET

FDA POSTPONES REVIEW OF RESPIVIR

FDA APPROVES HYGEIA PHARMACEUTICALS TRIALS

CYANOTECH GETS FUNDING FOR PRODUCTION FACILITY

SOUTH KOREA OKS BTG'S BIOLON By Brenda Sandburg

APS COMPLETES PHASE III TRIALS

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 16, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...